Literature DB >> 31338548

Low-calorie sweeteners augment tissue-specific insulin sensitivity in a large animal model of obesity.

Charles-Henri Malbert1, Michael Horowitz2, Richard L Young2,3.   

Abstract

PURPOSES: Whether low-calorie sweeteners (LCS), such as sucralose and acesulfame K, can alter glucose metabolism is uncertain, particularly given the inconsistent observations relating to insulin resistance in recent human trials. We hypothesized that these discrepancies are accounted for by the surrogate tools used to evaluate insulin resistance and that PET 18FDG, given its capacity to quantify insulin sensitivity in individual organs, would be more sensitive in identifying changes in glucose metabolism. Accordingly, we performed a comprehensive evaluation of the effects of LCS on whole-body and organ-specific glucose uptake and insulin sensitivity in a large animal model of morbid obesity.
METHODS: Twenty mini-pigs with morbid obesity were fed an obesogenic diet enriched with LCS (sucralose 1 mg/kg/day and acesulfame K 0.5 mg/kg/day, LCS diet group), or without LCS (control group), for 3 months. Glucose uptake and insulin sensitivity were determined for the duodenum, liver, skeletal muscle, adipose tissue and brain using dynamic PET 18FDG scanning together with direct measurement of arterial input function. Body composition was also measured using CT imaging and energy metabolism quantified with indirect calorimetry.
RESULTS: The LCS diet increased subcutaneous abdominal fat by ≈ 20% without causing weight gain, and reduced insulin clearance by ≈ 40%, while whole-body glucose uptake and insulin sensitivity were unchanged. In contrast, glucose uptake in the duodenum, liver and brain increased by 57, 66 and 29% relative to the control diet group (P < 0.05 for all), while insulin sensitivity increased by 53, 55 and 28% (P < 0.05 for all), respectively. In the brain, glucose uptake increased significantly only in the frontal cortex, associated with improved metabolic connectivity towards the hippocampus and the amygdala.
CONCLUSIONS: In miniature pigs, the combination of sucralose and acesulfame K is biologically active. While not affecting whole-body insulin resistance, it increases insulin sensitivity and glucose uptake in specific tissues, mimicking the effects of obesity in the adipose tissue and in the brain.

Entities:  

Keywords:  Brain connectivity; Compartmental analysis; Glucose uptake; Insulin sensitivity; Miniature pig; Statistical parameter mapping; Sweeteners

Mesh:

Substances:

Year:  2019        PMID: 31338548     DOI: 10.1007/s00259-019-04430-4

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  60 in total

1.  A computed tomography scan application to evaluate adiposity in a minipig model of human obesity.

Authors:  D Val-Laillet; S Blat; I Louveau; C H Malbert
Journal:  Br J Nutr       Date:  2010-07-09       Impact factor: 3.718

2.  Artificial sweeteners stimulate adipogenesis and suppress lipolysis independently of sweet taste receptors.

Authors:  Becky R Simon; Sebastian D Parlee; Brian S Learman; Hiroyuki Mori; Erica L Scheller; William P Cawthorn; Xiaomin Ning; Katherine Gallagher; Björn Tyrberg; Fariba M Assadi-Porter; Charles R Evans; Ormond A MacDougald
Journal:  J Biol Chem       Date:  2013-09-24       Impact factor: 5.157

3.  Artificial sweeteners induce glucose intolerance by altering the gut microbiota.

Authors:  Jotham Suez; Tal Korem; David Zeevi; Gili Zilberman-Schapira; Christoph A Thaiss; Ori Maza; David Israeli; Niv Zmora; Shlomit Gilad; Adina Weinberger; Yael Kuperman; Alon Harmelin; Ilana Kolodkin-Gal; Hagit Shapiro; Zamir Halpern; Eran Segal; Eran Elinav
Journal:  Nature       Date:  2014-09-17       Impact factor: 49.962

Review 4.  Metabolic effects of non-nutritive sweeteners.

Authors:  M Yanina Pepino
Journal:  Physiol Behav       Date:  2015-06-19

5.  Impulse control in the dorsolateral prefrontal cortex counteracts post-diet weight regain in obesity.

Authors:  Martin Weygandt; Knut Mai; Esther Dommes; Kerstin Ritter; Verena Leupelt; Joachim Spranger; John-Dylan Haynes
Journal:  Neuroimage       Date:  2015-01-07       Impact factor: 6.556

6.  Validation of [18F]fluorodeoxyglucose and positron emission tomography (PET) for the measurement of intestinal metabolism in pigs, and evidence of intestinal insulin resistance in patients with morbid obesity.

Authors:  H Honka; J Mäkinen; J C Hannukainen; M Tarkia; V Oikonen; M Teräs; V Fagerholm; T Ishizu; A Saraste; C Stark; T Vähäsilta; P Salminen; A Kirjavainen; M Soinio; A Gastaldelli; J Knuuti; P Iozzo; P Nuutila
Journal:  Diabetologia       Date:  2013-01-20       Impact factor: 10.122

7.  A method to estimate dispersion in sampling catheters and to calculate dispersion-free blood time-activity curves.

Authors:  Ole Lajord Munk; Susanne Keiding; Ludvik Bass
Journal:  Med Phys       Date:  2008-08       Impact factor: 4.071

8.  Effect of the artificial sweetener, acesulfame potassium, a sweet taste receptor agonist, on glucose uptake in small intestinal cell lines.

Authors:  Ye Zheng; Michael G Sarr
Journal:  J Gastrointest Surg       Date:  2012-09-05       Impact factor: 3.452

9.  Obesity and insulin resistance are associated with reduced activity in core memory regions of the brain.

Authors:  Lucy G Cheke; Heidi M Bonnici; Nicola S Clayton; Jon S Simons
Journal:  Neuropsychologia       Date:  2017-01-16       Impact factor: 3.139

10.  Measuring energy expenditure in the intensive care unit: a comparison of indirect calorimetry by E-sCOVX and Quark RMR with Deltatrac II in mechanically ventilated critically ill patients.

Authors:  Martin Sundström Rehal; Erik Fiskaare; Inga Tjäder; Åke Norberg; Olav Rooyackers; Jan Wernerman
Journal:  Crit Care       Date:  2016-03-05       Impact factor: 9.097

View more
  1 in total

1.  Pancreatic GLP-1r binding potential is reduced in insulin-resistant pigs.

Authors:  Charles-Henri Malbert; Alain Chauvin; Michael Horowitz; Karen L Jones
Journal:  BMJ Open Diabetes Res Care       Date:  2020-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.